Genomic Activation of Reveals a Candidate Therapeutic Axis in Bladder Cancer.
The gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of or lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. .
|Year of Publication||
2017 12 15
|PubMed Central ID||
R35 CA197568 / CA / NCI NIH HHS / United States